NTNG2
Disease associated variation - GWASdb
ChrPosSNP ID(dbSNP 142)RefAltOri SNP IDP-valueDrug NameDrug AnnoGWAS TraitHPO IDDO IDAATypeTrait or Drug
9135062771rs870591GArs8705910.0008283INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_drug
9135062771rs870591GArs8705918.28E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_drug
9135064702rs11243656GCrs112436560.000832INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_drug
9135064702rs11243656GCrs112436568.32E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_drug
9135064788rs11243657CTrs112436570.0009056INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148TintronGWASdb_drug
9135064788rs11243657CTrs112436579.06E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603TintronGWASdb_drug
9135070104rs7870760AGrs78707600.0008786INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_drug
9135070104rs7870760AGrs78707608.79E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_drug
9135073967rs3739930CTrs37399300.000911INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148Gcds-synonGWASdb_drug
9135073967rs3739930CTrs37399309.11E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603Gcds-synonGWASdb_drug
9135074063rs3739929TCrs37399290.0009136INFLIXIMAB|ADALIMUMAB|IMMUNOGLOBULIN GTUMOR NECROSIS FACTOR-ALPHA|ANTIRHEUMATIC AGENTS|ANTIBODIES, MONOCLONAL, HUMANIZED|TNFR-FC FUSION PROTEIN|ANTIBODIES, MONOCLONAL|RECEPTORS, TUMOR NECROSIS FACTORAnti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148AintronGWASdb_drug
9135074063rs3739929TCrs37399299.14E-04LEUCOVORIN|METHOTREXATESLCO1B1 PROTEIN, HUMAN|ORGANIC ANION TRANSPORTERSMethotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603AintronGWASdb_drug
9135042885rs883318AGrs8833186.48E-04Multiple complex diseasesHPOID:0000118NAGintronGWASdb_trait
9135051942rs7851167CArs78511671.28E-05Creatinine levelsHPOID:0012100|HPOID:0000077DOID:784AintronGWASdb_trait
9135053756rs7039329CTrs70393291.53E-05Creatinine levelsHPOID:0012100|HPOID:0000077DOID:784TintronGWASdb_trait
9135055814rs10116759ACrs101167597.71E-05Creatinine levelsHPOID:0012100|HPOID:0000077DOID:784AintronGWASdb_trait
9135062771rs870591GArs8705910.0008283Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_trait
9135062771rs870591GArs8705918.28E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_trait
9135064702rs11243656GCrs112436560.000832Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_trait
9135064702rs11243656GCrs112436568.32E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_trait
9135064788rs11243657CTrs112436579.06E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603TintronGWASdb_trait
9135070104rs7870760AGrs78707600.0008786Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months)HPOID:0001370DOID:7148GintronGWASdb_trait
9135070104rs7870760AGrs78707608.79E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603GintronGWASdb_trait
9135073967rs3739930CTrs37399309.11E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603Gcds-synonGWASdb_trait
9135074063rs3739929TCrs37399299.14E-04Methotrexate clearance (acute lymphoblastic leukemia)HPOID:0006721DOID:9952|DOID:12603AintronGWASdb_trait
9135080098rs11243667AGrs112436672.02E-04Multiple complex diseasesHPOID:0000118NAAintronGWASdb_trait
9135096767rs11243676GArs112436763.00E-06Systemic lupus erythematosusHPOID:0002725DOID:9074GintronGWASdb_trait
9135099486rs6597562CTrs65975621.10E-05Urinary metabolitesHPOID:0000079DOID:557CintronGWASdb_trait
9135114365rs2274853GArs22748536.63E-04Alcohol dependenceHPOID:0000707DOID:0050741CintronGWASdb_trait